NFKB1 and hepatocellular carcinoma: To test the hypothesis, the specific NF-κB signaling inhibitor, helenalin [12], was used to perform studies more deeply involving modified HCC cells, based on the above-mentioned conclusion that RUFY3 promoted EMT in HCC cells.